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Abstract
Purpose To evaluate pharmacokinetics, safety, and tol-
erability of abiraterone acetate (AA) in healthy men.
Methods Two phase I studies (dose-escalation study and
dose-proportionality study) were conducted in healthy men
aged 18–55 years. All subjects received 4 consecutive
single doses of AA (250, 500, 750 and 1,000 mg). The
dose-escalation study subjects (N = 33) received AA doses
in a sequential manner, starting with the lowest dose. The
dose-proportionality study subjects (N = 32) were ran-
domly allocated (1:1:1:1) to receive each of the 4 doses in a
four-way crossover design.
Results A dose-related increase in abiraterone exposure
wasobservedinbothstudies.Overtheevaluated doserange,
the mean abiraterone maximum plasma concentrations
increasedfrom26to112 ng/mLindose-escalationstudyand
from 40 to 125 ng/mL in dose-proportionality study; the
meanareaundertheplasmaconcentration–timecurvefrom0
to the last measurable plasma concentration increased from
155 to 610 ng.h/mL in dose-escalation study, and from 195
to 607 ng.h/mL in dose-proportionality study. In the dose-
proportionality study, abiraterone exposure was dose pro-
portional between 1,000 and 750 mg doses; however, the
exposure was slightly greater than dose proportional when
exposures at 500 and 250 mg doses were compared with the
exposure at 1,000 mg. Single doses of AA were well
tolerated in healthy men, and safety proﬁle was consistent
with its known toxicities in CRPC patients.
Conclusion Systemic exposure to abiraterone increased
with increasing doses of AA (250–1,000 mg) in healthy
men; AA was well tolerated in this population.
Keywords Abiraterone acetate  Dose-proportionality 
Pharmacodynamics  Pharmacokinetics  Prostate cancer
Introduction
Prostate cancer is the second leading cause of cancer
deaths, accounting for 9 % of all cancer-related death in
men [1]. Androgen deprivation therapy (ADT) is a standard
treatment for advanced, adjuvant, and non-adjuvant stages
of the disease and involves surgical (orchiectomy) or
medical (luteinizing hormone (LH)-releasing hormone
agonists, or antiandrogens) intervention [2, 3]. Although
ADT induces a remission in 80–90 % of patients with
advanced disease [4], majority of patients eventually
develop castration-resistant prostate cancer (CRPC), an
androgen-independent phenotype and the lethal form of the
disease, in which \20 % of patients survive beyond
3 years [5]. New therapeutic strategies, which can offer
better protection against CRPC, would be useful.
The enzyme 17a-hydroxylase/C17, 20-lyase (CYP17)
catalyzes critical reactions in the synthesis of androgens
[6]. Ketoconazole, the non-selective inhibitor of CYP17
enzyme, presents modest antitumor activity and is associ-
ated with an increase in androgenic steroids at disease
progression, indicating incomplete target blockade [7].
Abiraterone is a selective and irreversible inhibitor of
CYP17 enzyme and is 10–30-fold more potent than keto-
conazole [8]. A prodrug of abiraterone, abiraterone acetate
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Abiraterone acetate (ZYTIGA
) in combination with
prednisone is approved in the United States [9], Canada
[10], and Europe [11] for the treatment of male subjects
with metastatic castration-resistant prostate cancer, who
have received prior chemotherapy containing docetaxel.
The safety and tolerability of AA was demonstrated in
two dose-escalation studies in CRPC patients, and no dose-
limiting toxicity was identiﬁed at doses up to 2,000 mg
[5, 12]. In this report, we present the results from two phase
I studies (dose-escalation study and dose-proportionality
study) in healthy men, which evaluated pharmacokinetics
(PK) and safety of AA at doses of 250, 500, 750, and
1,000 mg. Additionally, in the dose-proportionality study,
pharmacodynamic evaluation was carried out to assess the
effect of abiraterone on levels of testosterone and LH.
Methods
Study population
Healthy men between 18 and 55 years of age (inclusive),
with body mass index within 18 to 32 kg/m
2 (inclusive),
were enrolled in both studies. Subjects were in good gen-
eral health as determined by medical history, physical
examination, vital signs, 12-lead electrocardiogram (ECG),
and clinical laboratory measurements; they had negative
test results for hepatitis B surface antigen, hepatitis C virus
antibody, human immunodeﬁciency virus antibody, selec-
ted drugs of abuse, and breathalyzer alcohol and had not
consumed nicotine or nicotine-containing products in
1 year before enrollment. All subjects used an acceptable
method of contraception from day-1 until 30 days follow-
ing the completion of studies.
Exclusion criteria were a signiﬁcant history or clinical
manifestation of any signiﬁcant diseases or disorders, his-
tory of stomach or intestinal surgery or resection that
would potentially alter absorption or excretion of drugs,
abnormal ECG, or hypersensitivity reaction to the study
drug or related compounds.
Subjects agreed to refrain from consuming grapefruit- or
caffeine-containing products (for 72 h before day-1 until
after collection of 96-h PK sample for the dose-escalation
study and throughout the study for the dose-proportionality
study) and alcohol-containing products (for 24 h before
day-1 until the end of study in both studies). Additionally,
they refrained from strenuous exercise from 48-h before
day-1 and during the period of conﬁnement at the clinical
research unit (CRU) for the dose-escalation study and
throughout the study for the dose-proportionality study.
Concomitant medications were not allowed during
both studies with the exception of acetaminophen and
non-steroidal anti-inﬂammatory drugs, which were allowed
after the 96-h PK sample collection.
Both studies were conducted in accordance with the
ethical principles that have their origin in the declaration of
Helsinki and that are consistent with good clinical prac-
tices, applicable regulatory requirements, and in compli-
ance with the respective protocols. The study protocols
were reviewed and approved by an independent institu-
tional review board (Florida, USA). All subjects provided
written informed consent before entering the studies.
Study designs
The dose-escalation study, conducted from December 17,
2008, to April 02, 2009, was an open-label study with a
14-day screening phase and up to 88-day treatment phase
(approximately 22 days for each of the 4 single-dose
cohorts). The dose-proportionality study, conducted from
March 30, 2010, to May 1, 2010, was an open-label, ran-
domized, four-way crossover study, with a 21-day
screening phase and a 28-day treatment phase (consisting
of 4 consecutive, 7-day treatment periods). Both studies
were conducted at Covance Clinical Research Unit Inc.,
Texas, United States of America.
Abiraterone acetate (manufactured by Pharmaceutical
International, Inc., Maryland) was provided as 250-mg
tablets. In both studies, AA was administered at doses of
250, 500, 750, and 1,000 mg/day. In the dose-escalation
study, these doses were administered to subjects in 4 dose
cohorts in a sequential manner, starting with the lowest
dose (250 mg/day). Dose administration for subsequent
cohorts was started at least 15 days after dosing of the
preceding cohort and after the safety data were reviewed
and assessed as not having any safety concerns such as
clinically signiﬁcant adverse event indicative of drug
intolerance; clinically signiﬁcant ﬁnding for physical
examination, 12-lead ECG, or vital signs; or clinically
signiﬁcant change in laboratory parameter. Due to an error
in PK sample processing at the CRU for the Cohort 2 dose
level (500 mg), another 500-mg dose level cohort was
added and designated as Cohort 2a. The bio-analytical data
for Cohort 2 was not evaluated.
In the dose-proportionality study, 32 eligible subjects
were randomized (1:1:1:1) to receive 1 of the 4 treatment
sequences: ADBC, BACD, CBDA, DCAB. Each treatment
sequenceincluded4doses ofAA:250 mg/day(treatmentA),
500 mg/day (treatment B), 750 mg/day (treatment C), and
1,000 mg/day (treatment D). For each subject, dose admin-
istration for subsequent treatment in the treatment sequence
was started 7 days after dosing of the preceding treatment.
All subjects fasted for at least 10 h before and 4 h after
AA administration in both studies. Subjects were conﬁned
to CRU one day before every administration of AA and
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addition, subjects visited CRU on days 3, 4, 5, 8, and 15 of
each dose cohort in dose-escalation study and on days 3, 4,
and 7 of each treatment period in the dose-proportionality
study, for study procedures.
Pharmacokinetic evaluation
During both studies, blood samples were collected for the
measurement of AA and abiraterone concentrations in
plasma; samples were collected from the peripheral vein
(via an indwelling catheter or direct venipuncture), within
0.5 h before the dose (predose sample) and at 0.25, 0.5, 1,
1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 h postdose.
Additionally, in the dose-proportionality study, blood
samples for evaluation of serum testosterone and LH were
also collected on day 1 (predose and 2 and 12 h postdose),
2, 3, 4, and 5 of each cohort and at the end of study or early
withdrawal visit.
Bioanalytical method
Concentrations of abiraterone and AA were determined
using a validated bioanalytical method employing ultra
performance liquid chromatography with tandem mass
spectrometric detection. The calibration range for abira-
terone was 0.2–200 ng/mL for the dose-escalation study
and 0.2–500 ng/mL for the dose-proportionality study. The
calibration range for AA was 0.2–50 ng/mL for both
studies.
Data analysis
For the dose-escalation study, non-compartmental analysis
was performed using WinNonlin (Pharsight Corporation,
Version 5.2). SAS version 9.1 was used for all statistical
calculations, tables, and plots. For the dose-proportionality
study, non-compartmental analysis was performed using
WinNonlin (Version 4.0.1b). SAS version 9.1 was used for
conﬁdence interval testing. Tables and plots were created
using PKAA 1.0, which utilized Microsoft Excel 2000.
Pharmacokinetic parameters
Pharmacokinetic parameters calculated from plasma con-
centration–time data were maximum plasma concentration
(Cmax), time to reach Cmax (tmax), and area under the
plasma concentration–time curve (AUC) from 0 to the last
measurable plasma concentration as calculated by the lin-
ear trapezoidal rule (AUC0–last); AUC extrapolated to
inﬁnity (AUC0–?), calculated as: AUC0–? = AUC0–last ?
Ct/kz,w h e r eC t was the last measurable plasma concentra-
tion and kz was the apparent terminal phase rate constant
calculated as the magnitude of the slope of the linear
regression of the log concentration versus time proﬁle during
the terminal phase; and apparent plasma terminal elimina-
tion half-life t1/2 (whenever possible), where t1/2 = (ln2)/kz.
Safety evaluations
Safety assessments included monitoring treatment-emer-
gent adverse events (TEAEs), clinical laboratory tests,
ECG, vital sign measurements, and physical examinations.
The severity of adverse events (AEs) was assessed using
theNationalCancerInstituteCommonTerminologyCriteria
for AEs (NCI CTCAE, version 3.0, grades 1, 2, 3, and 4)
[13]. In addition, total testosterone and LH levels on days-
1, 3, 5, 8, and 15 of each cohort in the dose-escalation study
and on day 1 (predose and 2 and 12 h postdose) and day 2
through day 5 in each treatment period in the dose-pro-
portionality study were evaluated. These evaluations were
repeated approximately 7 days after the end of study, for
subjects whose serum testosterone levels were not within
the normal limits or below the baseline value at the end of
study. In the dose-proportionality study, testosterone levels
were monitored every 7 days until the levels returned to
baseline or to within normal limits.
Statistical analysis
In both studies, PK analysis sets included all subjects who
received the study drug and had at least 1 valid PK
parameter estimate, and the safety analysis sets included all
subjects who received at least one dose of study drug.
Plasma concentration data of abiraterone and all esti-
mated PK parameters were summarized descriptively for
both studies. For the dose-proportionality study, least
squares means (LSM) and intra-subject variance were
estimated using a mixed-effect model, which included
treatment, period, and treatment sequence as ﬁxed effects
and participant as a random effect.
Sample size determination
Approximately 32 subjects were to be enrolled in the dose-
escalation study based upon samples sizes used in previous
PK studies of similar nature. For the dose-proportionality
study, the sample size of 24 subjects (using an estimated
intra-subject coefﬁcient of variation of 21 % for AUC0–last
and AUC0–?) was sufﬁcient for the point estimates of the
ratio of AUC0–last and AUC0–? to fall within 90–111 % of
the true value with 90 % conﬁdence. This sample size was
also sufﬁcient for the point estimate of the ratio of Cmax to
fall within 86–116 % of the true value with 90 % conﬁ-
dence using an estimated intra-participant coefﬁcient of
variation of 31 % for Cmax. Thirty-two subjects were
Cancer Chemother Pharmacol (2012) 69:1583–1590 1585
123randomized in the dose-proportionality study in order to
obtain at least 24 subjects who completed the study.
Results
Subject disposition and baseline characteristics
In the dose-escalation study, 40 men were screened, 33
were enrolled, 8 were assigned to each dose cohort, and all
completed the study. Dose cohort 2a (500 mg/day, repeti-
tion of cohort 2) included 7 subjects from cohort 2 and one
new participant. In the dose-proportionality study, 32 men
were enrolled, 27 completed the study, 3 discontinued due
to non-compliance, and 2 were lost to follow-up. Baseline
and demographic characteristics of subjects from both
studies are presented in Table 1.
Pharmacokinetics of abiraterone acetate
The PK analysis was not performed for AA as the majority
of plasma concentrations for AA were below the limit of
quantiﬁcation in both studies.
Pharmacokinetics of abiraterone
Following the administration of AA, the mean abiraterone
plasma concentrations increased relatively rapidly to peak
and declined in a biphasic manner, in both studies. The
mean concentration–time proﬁles of abiraterone obtained
in two studies are presented in Fig. 1.
Dose-escalation study
The abiraterone plasma concentrations and exposures
generally increased with increase in dose (Table 2). The
inter-subject variability [coefﬁcient of variation (CV %)]
for Cmax, AUC0–?, and AUC0–t ranged from 38.8 to
53.6 % for the 250 mg/day cohort, 46.9–60.0 % for the
500 mg/day cohort, 57.0–58.4 % for the 750 mg/day
cohort, and 32.7–40.8 % for the 1,000 mg/day cohort. The
mean t1/2 ranged from 11.1 to 14.7 h in Cohorts 1 through 4.
Abiraterone mean t1/2 and median tmax values appeared to
be independent of dose.
Dose-proportionality study
Median tmax occurred at 2 h after administration and mean
t1/2 ranged from 14.4 to 16.5 h. The mean exposures
increased with increase in dose (Table 2). Inter-subject
Table 1 Demographic and baseline characteristics of subjects (safety
analysis set)
Dose-
escalation
study (N = 33)
Dose-
proportionality
study (N = 32)
Age (years), mean (range) 37 (22–54) 35.5 (22–54)
Ethnicity, n (%)
Hispanic/latino 11 (33.3) 12 (37.5)
Non-hispanic/latino 22 (66.7) 20 (62.5)
Race, n (%)
White 19 (57.6) 22 (68.8)
Black or African
American
13 (39.4) 7 (21.9)
Asian 1 (3) 1 (3.1)
American Indian/
Alaska Native
0 1 (3.1)
Other 0 1 (3.1)
BMI (kg/m
2), mean (range) 26.0 (19.2–32.0) 26.6 (21–30)
BMI body mass index
250 mg Abiraterone acetate
500 mg Abiraterone acetate
750 mg Abiraterone acetate
1000 mg Abiraterone acetate
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Fig. 1 a Mean (SD) plasma concentration–time proﬁle of abiraterone
in dose-escalation study. b Mean (SD) plasma concentration–time
proﬁle of abiraterone in the dose-proportionality study
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123variability (CV %) was relatively high and ranged from
49.8 to 63.4 % for Cmax and 42.0–55.8 % for the AUCs.
Dose-normalized geometric mean ratios for Cmax and AUC
showed that abiraterone exposure decreased dose-propor-
tionally at 750 mg (90 % conﬁdence interval within
80–125 %) but not at 500 or 250 mg (Table 3).
Safety
In the dose-escalation study, overall, 23 TEAEs were
reported by 9 (27.3 %) subjects: 2 each from 250, 500, and
1,000 mg/day cohorts and 3 from 750 mg/day cohort; all of
the TEAEs were mild in nature. Overall, the most common
Table 2 Pharmacokinetic
parameters of abiraterone in
dose-escalation study and dose-
proportionality study
(pharmacokinetic analysis set)
Cmax = the maximum plasma
concentration; tmax = time to
reach Cmax; AUC0–last = area
under the plasma concentration–
time curve (AUC) from 0 to the
last measurable plasma
concentration; AUC0–? =
AUC extrapolated to inﬁnity
Parameter Dose cohort 1
(250 mg/day)
(n = 8)
Dose cohort 2
(500 mg/day)
(n = 8)
Dose cohort 3
(750 mg/day)
(n = 8)
Dose cohort 4
(1,000 mg/day)
(n = 8)
Dose-escalation study
Cmax (ng/mL), mean (SD) 25.9 (10.0) 76.6 (35.9) 57.4 (32.7) 112 (36.7)
tmax (h), median (min, max) 1.75 (1.0, 4.0) 2.02 (1.0, 3.0) 1.75 (1.0, 3.0) 1.75 (1.0, 3.0)
AUC0–last (ng.h/mL), mean (SD) 155 (83.3) 428 (257) 309 (180) 610 (249)
AUC0–? (ng.h/mL), mean (SD) 162 (84.7) 440 (254) 317 (183) 617 (249)
t1/2 (h), mean (SD) 11.1 (2.97) 14.6 (4.70) 14.7 (3.96) 12.7 (1.91)
Dose cohort 1
(250 mg/day)
(N = 27)
Dose cohort 2
(500 mg/day)
(N = 29)
Dose cohort 3
(750 mg/day)
(N = 28)
Dose cohort 4
(1,000 mg/day)
(N = 29)
Dose-proportionality study
Cmax (ng/mL), mean (SD) 39.9 (25.3) 67.0 (34.7) 87.0 (43.3) 125 (76.4)
tmax (h), median (min, max) 2.0 (1.0, 6.0) 2..0 (1.0, 4.0) 2.0 (1.0, 4.0) 2.0 (1.0, 4.0)
AUC0–last (ng.h/mL), mean (SD) 195 (109) 336 (156) 438 (189) 607 (298)
AUC0–? (ng.h/mL), mean (SD) 210 (105) 345 (155) 449 (189) 621 (300)
t1/2 (h), mean (SD) 14.4 (4.5) 15.3 (4.1) 16.5 (4.5) 16.0 (4.6)
Table 3 Dose-normalized pharmacokinetic parameters of abiraterone estimated in dose-proportionality study
Parameter Dose of abiraterone
acetate
(mg/day)
Least squares
means
a
Ratios
b 90 % conﬁdence
interval
c
Cmax (ng/mL) 250 117.97 124.06 102.94–149.52
500 108.77 114.38 94.96–137.78
750 98.00 103.06 85.52–124.21
1,000 95.09
AUC0–last (ng h/mL) 250 630.29 120.56 103.63–140.26
500 586.54 112.19 96.48–130.47
750 523.43 100.12 86.06–116.48
1,000 522.79
AUC0–? (ng h/mL) 250 750.79 128.66 111.62–148.31
500 663.45 113.69 98.71–130.96
750 579.33 99.28 86.13–114.44
1,000 583.54
Cmax = the maximum plasma concentration; AUC0–last = area under the plasma concentration–time curve (AUC) from 0 to the last measurable
plasma concentration; AUC0–? = AUC extrapolated to inﬁnity
PK pharmacokinetic
a Least squares (LS) means based on dose-normalized pharmacokinetic parameters from the mixed-effects model, transformed back to the linear
scale (i.e., geometric means)
b Ratio of parameter means (expressed as a percent), transformed back to the linear scale. Ratios are based on dose-normalized pharmacokinetic
parameters
c 90 % conﬁdence interval for ratio of parameter means (expressed as a percent), transformed back to the linear scale. Conﬁdence intervals are
based on dose-normalized pharmacokinetic parameters
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123TEAEs were diarrhea, nausea, vessel puncture site pain,
dizziness, and rhinorrhea, each reported by 2 (6.1 %)
subjects (Table 4). There were no discontinuations due to
TEAEs. There were no serious adverse events (SAEs) or
deaths reported during this study. No clinically signiﬁcant
changes were reported in hematological or clinical chem-
istry laboratory values, vital signs measurements, physical
examinations, or 12-lead ECGs.
In the dose-proportionality study, overall, 10 (31.3 %)
subjects [250 mg/day: 2 (7 %); 500 mg/day: 5 (17 %);
750 mg/day: 4 (14 %); and 1,000 mg/day: 3 (10 %)]
experienced TEAEs. Overall, the most common TEAEs
were headache, diarrhea, vessel puncture site pain,
extremity pain, decreased libido, and erectile dysfunction,
each reported by 2 (6.3 %) subjects (Table 4). None of the
TEAEs led to discontinuations during this study. No SAEs
or deaths were reported. There were no reports of TEAEs
related to increased mineralocorticoid levels. No clinically
signiﬁcant changes were observed in hematological or
clinical chemistry laboratory values (except that one par-
ticipant showed grade 2 abnormality: high bilirubin level
on day 17, which normalized on day 21), vital signs
measurements, physical examinations, or 12-lead ECGs.
Administration of AA resulted in decrease in serum tes-
tosterone levels and increase in serum LH levels; however,
none of these changes were clinically signiﬁcant.
In the dose-escalation study, mean serum total testos-
terone values were generally lowest on day 3 (the ﬁrst
postdose timepoint at which the testosterone levels were
measured in the dose-escalation study) and approached the
baseline values by day 5 (Fig. 2a), and mean serum LH
values were highest on day 3 and approached the baseline
values by day 8 (Fig. 2b). In the dose-proportionality
study, oral administration of AA 250–1,000 mg/day
resulted in transient decrease in the mean serum testoster-
one levels. The maximum decrease was observed at 12 h
postdose (the ﬁrst postdose timepoint at which the testos-
terone levels were measured in the dose-proportionality
study), with mean values returning to baseline by 72 h for
the 250 and 500 mg doses and by 144 h for the 750 and
1,000 mg doses (Fig. 2c). Administration of AA also
resulted in increase in mean serum LH levels, with maxi-
mum increase observed at 12 h postdose (Fig. 2d).
Discussion
Abiraterone acetate appeared to be fully converted to the
active moiety abiraterone, as the majority of plasma con-
centrations for AA were below the limit of quantiﬁcation
in both the studies. There was a dose-related increase in
exposure of abiraterone at doses from 250 to 1,000 mg in
the dose-escalation study as well as in the dose-propor-
tionality study. However, the dose-escalation study was not
formally designed to assess the dose-proportionality. In the
subsequent dose-proportionality study, statistical analysis
of dose-normalized geometric mean showed that the
decrease in abiraterone exposure from 1,000 to 750 mg
was dose proportional, but the decrease at 500 and 250 mg
was more than dose proportional (90 % CIs outside the
80–125 % range). In both studies, the mean t1/2 and median
tmax values for abiraterone were similar across the evalu-
ated dose range.
Total testosterone and LH levels measured in both
studies indicated that the observed reduction in serum
testosterone and elevation in serum LH following single
dose oral administration of AA were reversible. In the
dose-proportionality study, the maximum effect of AA on
mean serum total testosterone and LH levels occurred at
the 12-h postdose, which was the ﬁrst postdose timepoint at
which the testosterone levels were measured in this study.
Visual inspection of the concentration–time proﬁles for
abiraterone versus total testosterone and LH levels indi-
cated an indirect pharmacokinetic/pharmacodynamic effect
as shown by the delayed pharmacodynamic response.
In both studies, AA was safe and well tolerated in
fasting healthy men, over the evaluated dose range. The
most common TEAEs reported by at least 2 (6.1 %) sub-
jects were diarrhea, nausea, vessel puncture site pain,
dizziness, and rhinorrhea in the dose-escalation study and
headache, diarrhea, vessel puncture site pain, extremity
Table 4 Treatment-emergent adverse events (TEAEs) reported by
C2 subjects in dose-escalation study and dose-proportionality study
Dose-escalation study (N = 33)
Number of subjects with at least 1 TEAE 9 (27.3 %)
Diarrhea 2 (6.1 %)
Nausea 2 (6.1 %)
Site conditions 3 (9.1 %)
Vessel puncture site pain 2 (6.1 %)
Eye disorders 2 (6.1 %)
Nervous system disorders 2 (6.1 %)
Dizziness 2 (6.1 %)
Renal and urinary disorders 2 (6.1 %)
Rhinorrhea 2 (6.1 %)
Dose-proportionality study (N = 32)
Number of subjects with at least 1 TEAE 10 (31.3 %)
Headache 2 (6.3 %)
Diarrhea 2 (6.3 %)
Vessel puncture site pain 2 (6.3 %)
Pain in extremity 2 (6.3 %)
Psychiatric disorders 2 (6.3 %)
Libido decreased 2 (6.3 %)
Erectile dysfunction 2 (6.3 %)
1588 Cancer Chemother Pharmacol (2012) 69:1583–1590
123pain, decreased libido, and erectile dysfunction in the dose-
proportionality study. There were no deaths, SAEs, or AEs,
leading to discontinuation. There were no reports of
adverse events of interest related to mineralocorticoid
excess (e.g., ﬂuid retention/edema, hypertension, and
hypokalemia) and no adverse events of interest related to
liver function test abnormalities or cardiac disorders.
Abiraterone acetate was found to be safe and well tol-
erated in previous phase I and II studies in patients with
CRPC, when evaluated at doses of 250–1,000 mg/day;
also, no dose-limiting toxicity was observed up to dose of
1,000 mg/day [12, 14–16]. The safety proﬁle of AA
observed in the present two studies was consistent with
these studies and the other studies carried out in healthy
men [17].
Conclusion
Abiraterone acetate (250–1,000 mg/day) appeared to be
rapidly converted to abiraterone, following single dose,
oral administration in healthy men. Systemic exposure to
abiraterone increased with increasing doses of AA. In the
dose-proportionality study, abiraterone exposure was dose
proportional between 750 and 1,000 mg doses; however,
the exposure was slightly greater than dose proportional
when exposures at 500 and 250 mg doses were compared
with the exposure at the reference dose, 1,000 mg. Abira-
terone acetate was generally well tolerated in healthy men,
and the safety proﬁle was consistent with the known tox-
icities of AA observed in other clinical studies in patients
and in healthy men.
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Fig. 2 a Mean (SD) serum testosterone levels over time in dose-
escalation study. b Mean (SD) serum luteinizing hormone levels over
time in dose-escalation study. c Mean (SD) serum testosterone levels
over time in dose-proportionality study. d Mean (SD) serum
luteinizing hormone levels over time in dose-proportionality study.
n = 8 for all treatment groups except for 500 mg abiraterone acetate
group (n = 9)
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